Sunitinib
Active ingredient: Sunitinib Malate
In short: Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC
What is Sunitinib used for?
Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).
Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
⚠ Boxed warning (FDA's strongest warning)
Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended .
Sunitinib dosage
The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food.
The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food.
The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food.
To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions.
Indications | GIST | RCC | pNET
Advanced RCC | Adjuvant RCC
First dose reduction | 37.5 mg once daily | 37.5 mg once
daily | 37.5 mg once daily | 25 mg once daily
Second dose reduction | 25 mg once daily | 25 mg once
daily | NA | NA
Adverse Reaction | Severity | Dosage Modifications for
Sunitinib Malate Capsules
Hepatotoxicity | Grade 3 | Withhold until resolution to Grade 0 to 1 or baseline.
Resume at a reduced dose.
For recurring Grade 3 permanently discontinue.
Grade 4 | Permanently discontinue.
Cardiovascular events | Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) | Withhold until resolution to Grade 0 to 1 or baseline.
Resume at reduced dose.
Clinically manifested congestive heart failure (CHF) | Permanently discontinue.
Hypertension | Grade 3 | Withhold until resolution to Grade 0 to 1 or baseline.
Resume at a reduced dose.
Grade 4 | Permanently discontinue.
Hemorrhagic events | Grade 3 or 4 | Withhold until resolution to Grade 0 to 1 or baseline.
Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.
Thrombotic microangiopathy | Any Grade | Permanently discontinue.
Proteinuria or Nephrotic syndrome | 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome | Withhold until resolution to Grade 0 to 1 or baseline.
Resume at a reduced dose.
Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions | Permanently discontinue. …
How to take Sunitinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hepatotoxicity
Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity .
Cardiovascular Events
Advise patients to contact their healthcare provider if they develop symptoms of heart failure .
QT Prolongation and Torsade de Pointes
Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations .
Hypertension
Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension .
Hemorrhagic Events
Advise patients that sunitinib malate capsules can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding . …
Warnings & precautions
Do not take this medicine if: None.
Sunitinib malate can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure.
Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade ≤1 or baseline, then resume sunitinib malate at a reduced dose.
Discontinue sunitinib malate in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 x upper limit of normal (ULN) or with >5 x ULN and liver metastases has not been established.
Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported.
In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients.
In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to ≥50% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. …
Sunitinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling.
Hepatotoxicity
Cardiovascular Events
QT Interval Prolongation and Torsade de Pointes
Hypertension
Hemorrhagic Events
Tumor Lysis Syndrome
Thrombotic Microangiopathy
Proteinuria
Dermatologic Toxicities
Reversible Posterior Leukoencephalopathy Syndrome
Thyroid Dysfunction
Hypoglycemia
Osteonecrosis of the Jaw
Impaired Wound Healing
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (≥25%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia.
Gastrointestinal Stromal Tumor
The safety of sunitinib malate was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102). …
Drug interactions
Strong CYP3A4 Inhibitors
Coadministration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co-administered with strong CYP3A4 inhibitors .
Strong CYP3A4 Inducers
Coadministration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations . Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co-administered with CYP3A4 inducers .
Sunitinib malate is associated with QTc interval prolongation . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval.
About this medicine
Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as (2S)-2-hydroxybutanedoic acid with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1). The molecular formula is C22H27FN4O2 ● C4H6O5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is:
Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 0.4 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2.
Sunitinib malate capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30. The 12.5 mg capsule shell contains D&C Red No. 28, FD&C Blue No. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a9479e5f-914f-46ca-95c1-327c66457e47. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate